Shots: The P-III PEMPHIX study involves assessing of MabThera/Rituxan vs Mycophenolate Mofetil (MMF) in patients with moderate to severe active PV, requiring 60-120 mg/day oral prednisone (or equivalent) for 52wks. […]readmore
Tags : PEMPHIX Study
Shots: The P-III PEMPHIX Study (NCT02383589) involves assessing of Rituxan (1000mg, IV) vs mycophenolate mofetil (MMF) in patients with moderate to severe active pemphigus vulgaris The P-III PEMPHIX study met […]readmore